Prostate Cancer Clinical Trial
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
The purpose of this study is to assess the safety and tolerability of BMS-986406 administered alone and in combination with nivolumab in participants with advanced tumors.
Histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent malignant tumor. Eligible tumor types are non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction, castration-resistant prostate cancer (CRPC), ovarian, squamous cell carcinoma of the head and neck (SCCHN), bladder, melanoma, mesothelioma, triple negative breast cancer (TNBC), and soft tissue sarcoma, except for participants with tumors with central nervous system (CNS) metastases as the only site of active disease
Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), Prostate Cancer Working Group 3 (PCWG3) (for prostate cancer), or modified Response Evaluation Criteria in Solid tumors (mRECIST) (for mesothelioma)
Eastern Cooperative Oncology Group Performance Status of 0 or 1
Adequate organ function
Prior organ or tissue allograft
Untreated CNS metastases
Serious or uncontrolled medical disorders
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 11 Locations for this study
Los Angeles California, 90025, United States More Info
Philadelphia Pennsylvania, 19111, United States
Richmond Virginia, 23298, United States More Info
Brussels MO, 1200, Belgium More Info
Barcelona , 08916, Spain More Info
Madrid , 28041, Spain More Info
Malaga , 29010, Spain More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.